Impact of plasma 5-hydroxyindoleacetic acid, a serotonin metabolite, on clinical outcome in septic shock, and its effect on vascular permeability.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 07 2021
Historique:
received: 24 03 2021
accepted: 28 06 2021
entrez: 9 7 2021
pubmed: 10 7 2021
medline: 9 11 2021
Statut: epublish

Résumé

Septic shock is characterized by dysregulated vascular permeability. We hypothesized that the vascular permeability of endothelial cells (ECs) would be regulated by serotonin via serotonin-Rho-associated kinase (ROCK) signaling. We aimed to determine the impact of 5-hydroxyindoleacetic acid (5-HIAA) on septic shock as a novel biomarker. Plasma 5-HIAA levels and disease severity indices were obtained from 47 patients with sepsis. The association between 5-HIAA levels and severity indices was analyzed. Permeability upon serotonin stimulation was determined using human pulmonary microvascular ECs. 5-HIAA were significantly higher in septic shock patients than in patients without shock or healthy controls (p = 0.004). These elevated levels were correlated with severity indexes (SOFA score [p < 0.001], APACHE II [p < 0.001], and PaO

Identifiants

pubmed: 34238999
doi: 10.1038/s41598-021-93649-z
pii: 10.1038/s41598-021-93649-z
pmc: PMC8266895
doi:

Substances chimiques

Biomarkers 0
Indoles 0
Serotonin 333DO1RDJY
indole-3-lactic acid 5SW11R7M7M
rho-Associated Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14146

Références

Am J Respir Crit Care Med. 2009 Jun 15;179(12):1151-8
pubmed: 19299501
Am J Respir Cell Mol Biol. 2005 Jun;32(6):504-10
pubmed: 15778497
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2001 Nov;29(11):2051-9
pubmed: 11700394
N Engl J Med. 2018 Mar 01;378(9):797-808
pubmed: 29347874
Biochem Pharmacol. 2003 Nov 1;66(9):1673-80
pubmed: 14563478
J Gastroenterol. 2016 Nov;51(11):1040-1049
pubmed: 26984549
PLoS One. 2012;7(2):e31617
pubmed: 22319639
Anesth Analg. 2014 Feb;118(2):346-57
pubmed: 24445635
N Engl J Med. 2018 Oct 11;379(15):1431-1442
pubmed: 30304656
Lancet. 2018 Jul 7;392(10141):75-87
pubmed: 29937192
N Engl J Med. 2016 Jul 14;375(2):122-33
pubmed: 27181456
Antiviral Res. 2015 Feb;114:53-6
pubmed: 25512227
Mediators Inflamm. 2017;2017:6374283
pubmed: 28694565
J Phys Chem B. 2013 Oct 24;117(42):12850-6
pubmed: 23638866
Blood. 2013 Feb 7;121(6):1008-15
pubmed: 23243271
Biochem Biophys Res Commun. 2010 Sep 3;399(4):677-82
pubmed: 20691665
J Surg Res. 2015 Apr;194(2):520-527
pubmed: 25596653
Curr Opin Gastroenterol. 2009 Nov;25(6):503-11
pubmed: 19816171
Br J Anaesth. 2017 Oct 1;119(4):626-636
pubmed: 29121281
Brain Behav Immun. 1998 Dec;12(4):249-71
pubmed: 10080856
J Biol Chem. 2014 Apr 11;289(15):10466-10475
pubmed: 24570000
Chest. 2006 Jun;129(6):1673-82
pubmed: 16778289
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
Blood. 2012 Aug 9;120(6):1334-43
pubmed: 22544703
J Leukoc Biol. 2016 Nov;100(5):889-904
pubmed: 27587404
N Engl J Med. 2012 May 31;366(22):2055-64
pubmed: 22616830
Circulation. 1997 Oct 7;96(7):2280-6
pubmed: 9337201
J Cardiovasc Pharmacol. 2007 Mar;49(3):117-21
pubmed: 17414222
JAMA. 2018 Oct 9;320(14):1455-1463
pubmed: 30304428
J Biol Chem. 2006 May 12;281(19):13463-13470
pubmed: 16537538
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11427-32
pubmed: 23798437
Cell Tissue Res. 2014 Mar;355(3):621-33
pubmed: 24623445
Eur J Pharmacol. 2012 May 5;682(1-3):181-7
pubmed: 22374257
N Engl J Med. 2018 Mar 15;378(11):995-1003
pubmed: 29539291
J Neurol Sci. 2005 Nov 15;238(1-2):31-9
pubmed: 16005902
Circ J. 2013;77(10):2619-25
pubmed: 23912836
Front Immunol. 2014 Dec 18;5:653
pubmed: 25566264
J Neurosurg. 1992 Apr;76(4):571-7
pubmed: 1545249
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7695-7700
pubmed: 28674018
Annu Rev Med. 2009;60:355-66
pubmed: 19630576
J Biol Chem. 2007 Feb 2;282(5):2918-28
pubmed: 17142836
Am J Respir Cell Mol Biol. 2019 Aug;61(2):257-265
pubmed: 30811958
Reprod Sci. 2010 Sep;17(9):854-60
pubmed: 20601536
BMC Psychiatry. 2017 Feb 8;17(1):58
pubmed: 28178949

Auteurs

Takeshi Tanaka (T)

Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. ttakeshi@nagasaki-u.ac.jp.
Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. ttakeshi@nagasaki-u.ac.jp.

Masahiko Mori (M)

Department of Paediatrics, University of Oxford, Oxford, OX1 3SY, UK.

Motohiro Sekino (M)

Division of Intensive Care, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Ushio Higashijima (U)

Division of Intensive Care, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Masahiro Takaki (M)

Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Yoshiro Yamashita (Y)

Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Satoshi Kakiuchi (S)

Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Masato Tashiro (M)

Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Konosuke Morimoto (K)

Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Osamu Tasaki (O)

Acute and Critical Care Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Koichi Izumikawa (K)

Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH